Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
Eric Tetzlaff, MHS, PA-C, DFAAPA
Assistant Professor, Academic Clinician
Specialties
Treatment Philosophy
I chose to work at Fox Chase Cancer so that I could continue my career in oncology at an academic cancer center dedicated to providing quality care.
After graduating from Duke University's physician assistant program in 2004, I began my career in oncology as a physician assistant at the M.D. Anderson Cancer Center in Texas. I worked in the department of gastrointestinal medical oncology for four years, where I specialized in the treatment of gastroesophageal and hepatobiliary cancers. There, I had several manuscripts published in peer reviewed journals, and I presented original research at national oncology conferences.
At Fox Chase, I am focusing on the clinical care of patients with sarcomas and gastrointestinal cancers.
Clinical Locations
- Fox Chase Cancer Center
Primary Location
Educational Background
- MHS, PA Certificate, Duke University, Durham, NC, 2004
- BA, Psychology, University of Vermont, Burlington, VT, 1998
Certifications
- Pennsylvania Physician Assistant License, MA053353, 2008-Present
- National Commission on Certification of Physician Assistants, 1065312, 2004-Present
Memberships
- Association of Physician Assistants in Oncology (APAO)
- President, 2015-2016
- President Elect, 2014-2015
- Treasurer, 2013-2014
- American Society of Clinical Oncology (ASCO)
- CME Subcommittee Member, June 2014-May2018
- American Academy of Physician Assistants (AAPA)
Honors & Awards
- Employee of the Month, Fox Chase Cancer Center, May 2013
- 2018 Publishing Award, American Academy of Physician Assistants, June 2018
Research Interests
- Physician assistant workforce and utilization
- Gastrointestinal cancers
- Sarcoma
Selected Publications
Kosty MP, Acheson AK, Tetzlaff ED. Clinical oncology practice 2015: preparing for the future. Am Soc Clin Oncol Educ Book. 2015:e622-7. PubMed
Tetzlaff ED, Davey MP. Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor. J Adv Pract Oncol. 2013 Jul;4(4):238-50. PubMed
Tetzlaff ED, Cheng JD, Ajani JA. Thromboembolism in gastrointestinal cancers. Gastrointest Cancer Res. 2008 Nov;2(6):267-72. PubMed
Tetzlaff ED, Cheng JD, Ajani JA. Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag. 2008 Oct;4(5):999-1007. PubMed
Tetzlaff ED, Cen P, Ajani JA. Emerging drugs in the treatment of advanced gastric cancer. Expert Opin Emerg Drugs. 2008 Mar;13(1):135-44. PubMed
Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, Ajani JA. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2008;21(7):575-81. PubMed
Tetzlaff E, Polansky M, Carr K, Mares J, Vu L. Physician assistants in oncology. J Oncol Pract. 2007 Sep;3(5):283. PubMed
Tetzlaff ED, Correa AM, Baker J, Ensor J, Ajani JA. The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer. 2007 May 15;109(10):1989-95. PubMed
Tetzlaff ED. Factors to consider before referring patients for major cancer surgery. JAAPA. 2007 Mar;20(3):21-2. PubMed
Tetzlaff ED, Faust J, Ajani JA. Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. Gastric Cancer. 2006;9(2):140-3. PubMed
Tetzlaff ED, Hylton HM, DeMora L, et al: National Study of Burnout and Career Satisfaction Among Physician Assistants in Oncology: Implications for Team-Based Care. J Oncol Pract 14:e11-e22, 2018. Pubmed
